Recognition of Influenza A virus (IAV) by the innate immune system triggers pathways that 27 restrict viral replication, activates innate immune cells, and regulates adaptive immunity. 28
file. The concatenated file was run through a UMAP analysis of the surface markers CD11b, 196 CD4, CD20, CD123, CD68, CD14, Siglec 8, CD56, CD8, HLA-DR, CD3, CD1c, CD141, 197 CD16. Post-UMAP analysis, distinct cell subsets were identified by mapping expression of 198 on February 25, 2020 at CARDIFF UNIVERSITY http://jvi.asm.org/ Downloaded from 9 specific subset markers back onto the UMAP to define populations of immune cells. Subsets 199 were defined as follows: CD4 + T cells, CD3 + CD4 + CD20 -; CD8 + T cells, CD3 + CD20 -CD8 + ; B 200 cells, CD3 -CD20 + ; NK cells, CD3 -CD20 -CD56 + ; CD14 + Monocytes, CD16 -201 Aldrich), 250 IU/mL IL-4 and 800 IU/mL GM-CSF into a 6-well plate and incubated at 37C 217 for 2 days. After 2 days 1.5ml of medium was removed from each well, and 1.5 mL of fresh 218 medium supplemented with 500 IU/mL IL-4 and 1600 IU/mL GM-CSF was added. After a 219 further 3-day incubation, cells were harvested at the immature phenotype and assayed, or 220 further matured with LPS at 10 g/mL for 24 hours. The healthy control hIPSC line Kolf2 was acquired through the Human Induced Pluripotent 225 Stem Cells Initiative Consortium (HipSci; www.hipsci.org), through which it was also 226 characterized (23). Generation of IRF5 -/-iPSCs has been previously described (16). Briefly, 227
Kolf2 iPSCs were dissociated to single cells and nucleofected (Amaxa2b nucleofector, 228 LONZA) with Cas9 coding plasmid (hCas9, Addgene 41815), sgRNA plasmid (left  229   CRISPR_IRF5 CCAAGTGGAAGGCCAACCTGCGC; right CRISPR_IRF5 230 GACTTCCGCCTCATCTACGACGG) and donor plasmid, containing 5' and 3' homology 231 arms for IRF5 targeting and pL1-EF1αPuro-L2 cassette. Post nucleofection, cells were 232 selected for up to 11 days with 0.25 μg/mL puromycin, after which individual colonies were 233 picked onto 96-well plates, grown to confluence and then replica plated. To genotype 234 individual clones from a 96-well replica plates, cells were lysed and used for PCR 235 amplification with LongAmp Taq DNA Polymerase (NEB). Insertion of the cassette into the 236 correct locus was confirmed by visualizing on 1% E-gel (Life Tech.) PCR products were 237 generated by gene specific and cassette specific primers, with single integration of cassette 238 confirmed by a qPCR copy number assay. Positive clones were then screened for damage to 239 the non-targeted allele via PCR and Sanger sequencing. To generate our complemented IRF5 240 iPSC line (IRF5 Comp ) and restore expression of functional IRF5 in the IRF5 -/-iPSCs, we 241 generated the AAVS1 EF1a-IRF5-PGK-puro targeting vector by Gibson assembly. The 242
Gibson assembly product was transformed into OneShot TOP10 chemically competent E. 243 coli (Thermo Fisher Scientific) and positive colonies were picked. Isolated plasmids from the 244 positive colonies were taken to confirm the presence and sequence of EF1α-IRF5 in the 245 targeting vector by restriction digests, PCR and sequencing. Subsequently, the targeting 246 vector was transformed into competent E. coli to isolate endotoxin-free plasmids to transform 247 into the IRF5 -/-iPSCs. We transfected the mutant human hIPSCs with TALEN-L 248 on February 25, 2020 at CARDIFF UNIVERSITY http://jvi.asm.org/ Downloaded from 11 (CCCCTCCACCCCACAGT), TALEN-R (AGGATTGGTGACAGAAA) and targeting 249 vector via nucleofection (Amaxa Biosystems). The resultant targeted cells were selected on 250 puromycin for 7 days and the surviving colonies were picked and expanded. The positive 251 clones were confirmed by RT-qPCR for IRF5 expression and flow cytometry for protein 252 expression. Prior to differentiation, iPSCs were grown feeder-free using the Essential 8 Flex 253
Medium kit (Thermo Fisher Scientific) on Vitronectin (VTN-N, Thermo Fisher Scientific) 254 coated plates as per manufacturer's instructions to 70-80% confluency. iPSCs were harvested 255 for differentiation using Versene solution (Thermo Fisher Scientific). 256
257

Differentiation of iPSCs to dendritic cells and macrophages 258
To differentiate iPSCs to dendritic cells slight modifications were made to a previously 259 published protocol (24). Briefly, upon reaching confluency iPSCs were harvested and plated 260 into Essential 8 Flex medium supplemented with 50 ng/mL BMP-4 (Bio-Techne), 20 ng/mL 261 SCF (Bio-Techne), 50 ng/mL VEGF (Peprotech EC Ltd.), and 50ng/mL GM-CSF (Peprotech 262 EC Ltd.) in ultra-low attachment plates (Corning). Media was changed to X-VIVO-15 263 (Lonza), with sequential removal of BMP-4 by day 5, VEGF by approximately day 14 and 264 SCF by approximately day 19. In addition, IL-4 (Peprotech EC Ltd.) was added sequentially 265 in increasing concentrations, starting from approximately day 12 at 25 ng/mL and increasing 266 to 100 ng/mL by approximately day 20. By day 20, floating immature DCs were harvested 267 from ULA plates, filtered through 70M filters (Corning), counted and seeded at 1 x 10 6 per 268 well of 6 well CellBind plates (Corning) in X-VIVO-15 media supplemented with 100 ng/mL 269 IL-4 and 50 ng/mL GM-CSF. iPS-DCs were used for assays at the immature phase between 
IRF5 mediates inflammatory cytokine and myeloid cell responses to Influenza A virus 381 infection in mice 382
The mouse is the primary experimental model for studying immunological response to IAV, 383 where it has been demonstrated that excessive inflammatory cytokine and cellular immune 384 responses promote lung pathology (2, 26, 27). We first used this model to assess whether 385 IRF5 impacts influenza-induced immune responses during IAV infection in vivo, using the 386 low pathogenicity murine-adapted H3N2 Influenza A virus (A/X-31). Prior studies have 387 indicated that viral infections of Irf5 -/mice lead to reduced cytokine production in 388 comparison to wild type (WT) controls (14, 17, 28). In accordance, we observed a significant 389 reduction in early cytokine release in Irf5 -/mice, with IL-23, IFN-, TNF-, MCP-1, IL-6, 390 IL-17A, IL-1, IL-12p70, GM-CSF, IL-1 and IL-27 all significantly reduced in the 391 Bronchoalveolar Lavage (BAL) of Irf5 -/mice in comparison to WT controls 2 days post-392 infection (p.i) ( Fig. 1A) , with some cytokines remaining significantly reduced in Irf5 -/mice 4 393 days p.i (Fig. 1A) . In contrast to other viral infections (17), IFN- or IFN- production in 394 response to influenza infection were unaltered ( Early reduction in inflammatory cytokine production in Irf5 -/mice was accompanied by a 401 moderate amelioration of IAV-induced weight loss ( Fig. 2A) . Interestingly, a recent study 402 reported that reduced IAV-induced cytokine production in Irf5 -/mice was associated with 403 reduced virus replication (28) . However, at a time-point where we observed substantially 404 reduced cytokine production (day 2 p.i), we observed no alteration in IAV load in Irf5 -/mice 405 ( Fig. 2B ), nor did we observe altered virus load in Irf5 -/mice at a later timepoint of 4 days p.i 406 were observed at 2 days p.i (Fig. 2C ). Importantly, lower cytokine responses in Irf5 -/mice 414 were accompanied by significant reductions in IL-6 + cDCs and TNF- + cDCs, interstitial 415 macrophages, cDCs and pDCs in the airways (Fig. 2D ). Thus, these data suggested that Irf5 416 plays a key role in shaping the early innate inflammatory response during influenza infection 417 and point to a central role for myeloid cells in promoting IRF5-driven viral disease. 418 419
Myeloid cells in human lung express high levels of IRF5 420
Although the mouse is a useful model for probing immune responses to IAV, numerous 421 differences exist between the mouse and human immune system. It was therefore important 422 on February 25, 2020 at CARDIFF UNIVERSITY http://jvi.asm.org/ Downloaded from 18 to investigate the role of human IRF5 in IAV-induced immune responses. We first measured 423 IRF5 expression in multiple cell subsets in human lung samples using CyTOF (Fig. 3A) . 424
Using lung samples from four independent donors, we identified significantly different IRF5 425 expression dependent on cell subset (p = 0.0252, R-Square = 0.9098) ( Fig. 3B) , with cells of 426 the myeloid lineage, particularly eosinophils, basophils and monocytes, displaying highest 427 expression of IRF5 in human lung. Expression was higher in CD1c + DCs and CD141 + DCs 428 than in lung resident macrophages, where expression was relatively low. Furthermore, when 429 IRF5 expression data was combined for all myeloid cell subsets and all lymphoid cell subsets 430 ( Fig. 3C ), expression of IRF5 was significantly higher in myeloid cells in comparison to 431 lymphoid cells (median expression myeloid = 6.01, median expression lymphoid = 1.79; p = 432 0.0001), suggesting that IRF5 expression is highest in the myeloid compartment. 433 434 iPSCs with a biallelic mutation in IRF5 can be differentiated into conventional dendritic 435 cells 436
Given that, in the human lung, IRF5 expression was highest in cells of the myeloid lineage 437 and that in mice Irf5 promoted pro-inflammatory cytokine production by myeloid cells in 438 response to IAV infection, we next sought to establish a human myeloid cell model to 439 scrutinize the role of IRF5 in myeloid cell cytokine response to IAV. We differentiated a 440 hIPSC line with a biallelic mutation in IRF5 generated using CRISPR/Cas9 genome editing 441 (16) and the parental line Kolf2, into iPS-DCs using a published differentiation strategy (24). 442
We also generated a complemented isogenic control line for IRF5 -/-(hereafter "IRF5 Comp ") to 443 confirm IRF5-dependency of any phenotypes observed (32). To confirm gene editing 444 strategies, we examined the expression of IRF5 in Kolf2, IRF5 -/and IRF5 Comp iPS-DCs. 445 CD86 and CLEC9A, which have been shown to be expressed by human CD141 + DCs (35) . 470
We did not detect CD303 expression, a marker for pDCs or CD1c, the marker for the other 471 CD83 and CD86 in all three iPSC lines after differentiation to iPS-DCs, and loss of 475 expression of the pluripotency markers NANOG and POU5F1 (Fig. 5C ). Morphology of 476
Kolf2, IRF5 -/and IRF5 Comp iPS-DCs in culture was indistinguishable (Fig. 5D ). Taken 477 together, these data suggest that neither IRF5 deficiency nor TALEN-based engineering 478 influence iPSC differentiation. 479
480
IRF5 enhances IAV-induced inflammatory cytokine production in iPS-DCs 481
After confirming that IRF5 deficiency did not alter iPS-DC surface phenotype or morphology 482 ( Fig. 5 ) and that iPS-DCs exhibit similar cytokine profiles to human monocyte-derived DCs 483 after IAV stimulation (Fig. 4D) , we next used iPS-DCs to determine whether IRF5 has a cell-484 intrinsic role in human DC cytokine production, in particular the pro-inflammatory cytokines 485 IL-6 and TNF-. Despite a protective role for IL-6 being reported in murine models of IAV 486 infection (37, 38), high production of IL-6 is linked to severity of symptoms in humans 487 patient cohorts (39, 40) , whereas TNF- has been shown to enhance cellular inflammation 488 and pathology during IAV infection (26). 489 490 24 hours after stimulation of iPS-DCs with IAV, IL-6 and TNF- production by IRF5 -/-iPS-491
DCs was significantly reduced in comparison to Kolf2 iPS-DCs whereas cytokine production 492 was restored in IRF5 Comp iPS-DCs (Fig. 6A , iPS-DCs). IRF5 deficiency had no impact on 493 virus entry, as indicated by comparable influenza nucleoprotein (NP) staining after 24 hours 494 ( Fig. 6B & C) . In addition, there was no significant difference in cell viability after IAV 495 IRF5 -/and IRF5 Comp iPS-DCs (Fig. 6D) . Moreover, gene complementation has previously 500 been used to inhibit immune responsiveness in the context of restoration of expression of the 501 inhibitory IL-10 receptor into IL10RB -/-iPS-derived myeloid cells (33). Thus we do not 502 believe that restored cytokine responsivess of complemented IRF5 -/cells is a consequence of 503 non-specific induction of cytokine secretion by the complementation process, but instead is 504 due to IRF5 itself. Collectively, these data suggest that IRF5 deficiency selectively alters iPS-505 DC cytokine production after exposure to IAV. In addition, to probe IRF5 deficiency in a 506 different myeloid cell lineage, we differentiated IRF5 -/-, Kolf2 and IRF5 Comp iPSCs to 507 macrophages (iPSDMs) using a slightly modified version of a previously published protocol 508 (22), demonstrating a similar significant reduction in IL-6 and TNF- production as observed 509 in iPS-DCs (Fig. 6A, iPSDMs) . In some experimental systems, IRF5 mediates virus-induced production of type I IFN (17, 514 41). Given that type I IFN is implicated in driving influenza-induced inflammatory cytokine 515 responses (42), we assessed whether IRF5 deficiency impacted influenza-induced IFN 516 production. Blocking type I IFN reduced IAV-induced IL-6 and TNF- production albeit, in 517 the case of IL-6, not to levels produced by IRF5 -/-iPS-DCs (Fig. 7A ). Furthermore, IRF5 had 518 no impact on type I IFN secretion by iPS-DCs (Fig. 7B ). Thus, although type I IFN enhanced 519 IRF5-induced pro-inflammatory cytokine secretion, the production of type I IFN by iPS-DCs 520 was not an IRF5-regulated process. Kolf2 iPS-DCs significantly abated IL-6 production whereas TLR7 inhibition in IRF5 -/-iPS-540
DCs did not further reduce IAV-induced IL-6 responses (Fig. 8F) . These data suggest that 541 IRF5 promotes TLR7 mediated cytokine responses following IAV detection by human DCs. 542
However, IAV-induced cytokine secretion was incompletely inhibited by TLR7 blockade in 543
Kolf2 iPS-DCs, suggesting that other PRRs contribute to IRF5-mediated responses. IKK 544 has been shown to play a crucial role in IRF5 and NF-B activation (11). In support of this, 545 pre-treatment of IAV-stimulated iPC-DCs with the IKK inhibitor IMD 0354 dramatically 546 reduced IAV-induced cytokine production by iPS-DCs (Fig. 8B) Here, using iPS-DCs as a model system, we have shown that IRF5 expression by myeloid 552 cells is important in driving the inflammatory response to IAV, without impacting viral 553 uptake by iPS-DCs or DC maturation. Using various blocking assays and stimulation with 554 TLR/RLR ligands, we show that IRF5 is most likely acting downstream of TLR7 and, 555 possibly, RIG-I signaling to drive the production of pro-inflammatory cytokines. 556 557 Given that IFN-stimulated genes contribute to anti-influenza immunity (48), to identify 558 whether IFR5 and/or related pathways could be safely exploited to dampen inflammatory 559 cytokine responses to influenza it is important to understand the relationship between IRF5 560 and virus-induced type 1 IFN. We found that IRF5 -/-iPS-DCs and Irf5 -/mice were not 561 deficient in type I IFN production, but that type I IFN enhances the IRF5-mediated 562 inflammatory cytokine response, a process associated with IFN-mediated induction of TLR7 563 and RIG-I. Although certain studies have reported a role for IRF5 in type I IFN induction 564 directly in certain contexts (28, 46, 49) functional redundancy between IRF proteins may 565 exist [46] . Also, although a role for IRF5 in promoting type 1 IFN secretion following 566 influenza infection in vivo has been reported, the same studies observed reduced virus 567 replication in Irf5 -/mice, precluding the possibility to uncouple decreased virus replication 568 and subsequent pattern recognition receptor stimulation from a direct influence of IRF5 on 569 type 1 IFN expression. Furthermore, early in vivo studies of Irf5 responses to viruses may 570 have been confounded by a Dock2 mutation prevalent in Irf5 -/mouse colonies (50). Also, it 571 has been demonstrated in vitro that, unlike IRF3 and IRF7, IRF5 does not bind to the virus-572 on February 25, 2020 at CARDIFF UNIVERSITY http://jvi.asm.org/ Downloaded from 24 response elements in IFN promotors (51). IRF5-mediated induction of type I IFN may also be 573 virus-specific, at least in vitro, with NDV, VSV and HSV-1 infection shown to activate IRF5 574 but lead to induction of distinct IFNA gene subtypes in human cell lines (52). IRF3 and IRF7 575 are activated by IAV, and these transcription factors have been shown to be necessary for 576 inducing type I IFN after IAV infection (53, 54). Therefore, we suggest that after sensing of 577 IAV by dendritic cells, IRF3, IRF5, and IRF7 are induced, resulting in the production of type 578 I IFN and inflammatory cytokines, with the type I IFN induced by IRF3 and IRF7 579 exacerbating IRF5 activation, likely in part through induction of TLR7 and, possibly, RIG-I 580 expression. In the context of influenza pathogenesis, our data imply that IRF5 could be safely 581 targeted to limit virus-induced pro-inflammatory cytokine production without affecting IFN 582 production and associated induction of antiviral effector genes. 583
584
The phenotype of reduced inflammatory cytokines observed in our iPS-DC model was also 585 evident in vivo using Irf5 -/mice. Although we observed no mortality in either WT or Irf5 -/-586 mice (Forbester J & Humphreys I, unpublished data), we observed reduced cytokine 587 production by myeloid cells that correlated with reduced cellular pulmonary infiltration and a 588 moderate impact on virus-induced weight loss. Although Irf5 -/mice have previously been 589 shown to be less susceptible to IAV-induced pathology (28) , in this study we were able to de-590 couple viral load and inflammatory cytokines in the early stages of infection, demonstrating 591 that the enhanced pathology in WT compared to Irf5 -/mice was immune-mediated rather 592 than a consequence of heightened virus replication. Why differences exist between our data 593 and those obtained by Chen et al (28) is unclear, although this may reflect the different 594 influenza strains (H3N2 versus H1N1) used in these experiments. Irrespective, the data 595 presented herein demonstrates that IRF5 modulates viral pathogenesis via the regulation of 596 inflammation and not virus replication, and that targeting this pathway as an adjunct therapy 597 on February 25, 2020 at CARDIFF UNIVERSITY http://jvi.asm.org/ Downloaded from 25 to antiviral drug treatment may represent an effective therapeutic approach to treatment of 598 influenza pathogenesis. 599
600
Although the mouse provides a useful model to study viral pathogenesis there are inherent 601 immunological differences between mice and humans (55). Therefore, we wanted to establish 602 a human cell system amenable to genetic manipulation, so that gene function can be 603 understood in the context of a human cellular environment. Given that primary human 604 myeloid cells are difficult to genetically manipulate and access in large numbers, hIPSCs 605 offer a solution; once hIPSCs are generated they can be differentiated down multiple cellular 606 lineages, providing the opportunity to study gene function in multiple different cell types, 607 with a defined genetic background. In addition, as hIPSCs are self-renewing, starting material 608 is an unlimited resource. Furthermore, many research groups have shown that hIPSCs can be 609 relatively easily genetically manipulated using tools such as Zinc finger nucleases, TALENs 610 and CRISPR-Cas9 systems (56). Here, we show that iPSCs can be differentiated into DCs 611 expressing markers of human CD141 + myeloid DCs. However, the levels of the specific 612 lineage markers for CD141 + DCs, CLEC9A and XCR1 were quite low in our DC 613 populations, which has been previously described (24). The complex environment and array 614 of signals DC progenitors are exposed to during development presents a challenge to 615 replicate in vitro. However, fundamental understanding of human DC development is 616 expanding, and in the future knowledge of detailed changes in the transcriptional profile of 617 these cells during development can be applied to help refine differentiation protocols. 618
However, iPS-DCs described herein expressed multiple DC lineage markers, suggesting that 619 our differentiation protocol is sufficient to derive DC-like cells. In addition, we demonstrated 620 that after differentiation into iPSDMs, IRF5 -/cells are also deficient in IL-6 and TNF- 621 production, demonstrating for the first time that virus induced immune responses, including 622 on February 25, 2020 at CARDIFF UNIVERSITY http://jvi.asm.org/ Downloaded from 26 cytokine secretion, can be investigated in iPS-derived cells of multiple myeloid lineages that 623 contain biallelic mutations, thus demonstrating the flexibility of iPSCs as tools to study 624 immune responses to pathogens in multiple cell types. 625
626
In two independent studies response eQTLs (reQTLs) were found in IRF5 after stimulation of 627 cells with virus or TLR ligands (57, 58), suggesting that variation within the IRF5 locus may 628 be important in driving differences in expression. It would be interesting in future studies to 629 see if SNPs which drive higher IRF5 expression in human macrophages and DCs also 630 correlate with a heightened inflammatory response to viruses such as IAV, as our data 631 suggest that such individuals may be preferentially susceptible to influenza pathogenesis and 632 imply that targeting high IRF5 levels in these individuals could reduce inflammation without 633 impacting virus control. As well as being a useful tool to knockout genes to assess cell-634 specific function as we have shown here, iPS-DCs could also be used as a tool to explore 635 
